These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
804 related articles for article (PubMed ID: 29223483)
1. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies. Boef AGC; van der Klis FRM; Berbers GAM; Buisman AM; Sanders EAM; Kemmeren JM; van der Ende A; de Melker HE; Rots NY; Knol MJ Vaccine; 2018 Jan; 36(3):400-407. PubMed ID: 29223483 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596 [TBL] [Abstract][Full Text] [Related]
3. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial. van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R; Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305 [TBL] [Abstract][Full Text] [Related]
8. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA; Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472 [TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America. López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Gimenez-Sanchez F; Kieninger DM; Kueper K; Martinon-Torres F; Bernaola E; Diez-Domingo J; Steul K; Juergens C; Gurtman A; Giardina P; Liang JZ; Gruber WC; Emini EA; Scott DA; Vaccine; 2011 Aug; 29(35):6042-8. PubMed ID: 21704105 [TBL] [Abstract][Full Text] [Related]
14. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640 [TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777 [TBL] [Abstract][Full Text] [Related]
16. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054 [TBL] [Abstract][Full Text] [Related]
17. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661 [TBL] [Abstract][Full Text] [Related]
18. Disparate kinetics in immune response of two different Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024 [TBL] [Abstract][Full Text] [Related]
19. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine. Xu J; Stek JE; Ziani E; Liu GF; Lee AW Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742 [TBL] [Abstract][Full Text] [Related]
20. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers. Lee AW; Jordanov E; Boisnard F; Marshall GS Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]